ClinicalTrials.gg
RecruitingNCT06426992Updated Apr 13, 2026

Clinical Effectiveness of Microwave Ablation Using Starwave Microwave Generator for Hepatic Malignancies

An interventional study of Starwave Microwave Ablation System and Microwave Ablation in Liver Malignant Tumors, sponsored by Seoul National University Hospital. Recruiting at 1 site in South Korea. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
128
Allocation
Not applicable
Ages
20 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Carcinoma, Hepatocellular by Seoul National University Hospital — 9 open to participants now, 14 under way, none of them phase 3. Carcinoma, Hepatocellular · Seoul National University Hospital.

Planned enrollment
11th of 52
128 · median 85
Started
2024
the only one that year
No phase
35 of 61
3 open now
Primary completion
2026-08
later than 5 of 13 live
Registered
54th of 61
by date

Among the 61 studies in Carcinoma, Hepatocellular by Seoul National University Hospital, this one is the 11th largest by planned enrollment of the 52 interventional ones that give a count, is the only one that started in 2024, is one of 35 with no phase, reaches primary completion later than 5 of the 13 other live ones, and was the 54th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

9 of the 61 studies in Carcinoma, Hepatocellular by Seoul National University Hospital are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 20 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Carcinoma, Hepatocellular by Seoul National University Hospital, or all of them as a file.
02

Study summary

The purpose of this study is to determine the technical success rate of creating a safety margin of 5 mm or more including the tumor by performing image-guided percutaneous microwave thermal therapy using a microwave generator and antenna developed by StarMed for the treatment of small liver cancer and the 1-year local recurrence rate based on follow-up imaging tests.

Read the detailed description

Study Design and-Purpose: This is a prospective, single-center clinical study to evaluate the effectiveness of microwave ablation (MWA) for treating small liver malignancies using the Starwave™ microwave generator and antenna. The primary purpose is to assess the 12-month local tumor recurrence rate. Secondary objectives include evaluating the technical success of achieving a ≥5 mm safety margin around the tumor, as well as procedural time, ablation volume, and safety.

Background: Hepatocellular carcinoma (HCC) and metastatic liver tumors are major causes of cancer-related death worldwide. For small tumors (≤5 cm), thermal ablation techniques like Radiofrequency Ablation (RFA) and Microwave Ablation (MWA) are common treatment options, especially for patients who are not candidates for surgery. MWA offers several advantages over traditional RFA, including faster ablation times, larger ablation zones, and less susceptibility to the "heat sink" effect from nearby blood vessels. Achieving a sufficient safety margin (5-10 mm) around the tumor is critical to prevent local recurrence.

The Starwave™ MWA system, a domestic product in Korea, can deliver a higher maximum power output (150W) compared to some existing systems (e.g., Emprint™, 100W), potentially enabling more efficient energy delivery and larger, more spherical ablation zones. This study aims to prospectively evaluate the 12-month outcomes of this system, as no such data currently exists.

Eligibility Criteria The study will enroll 128 patients who meet the following key criteria. Inclusion Criteria: 1) Age 20-85 years; 2) Diagnosed with liver malignancy ≤4 cm in size (HCC, metastatic cancer, or recurrent/residual HCC); 3) Child-Pugh class A or B liver function; 4) Provided informed consent.

Exclusion Criteria:1) More than 3 malignant liver tumors; 2)Tumors larger than 4 cm; 3) Diffuse infiltrative type cancer;4) Severe coagulopathy or liver failure (Child-Pugh class C); 5) Tumor invasion into major hepatic vessels; 6) Intervention and Follow-up

Intervention: Patients will undergo percutaneous MWA using the Starwave™ system. The procedure will be performed under image guidance (ultrasound, often with CT/MR fusion imaging) with one or two 13-gauge antennas. The goal is to ablate the tumor and a 5-10 mm safety margin.

Follow-up: A CT or MRI scan will be performed immediately post-procedure to assess technical success. Subsequent follow-up with CT or MRI will occur approximately every 3 months for up to 12 months to monitor for local tumor recurrence.

Outcome Measures

  1. Primary Outcome Measure: Local Tumor Recurrence Rate at 12 Months: The percentage of patients with tumor recurrence at the ablation site within 12 months, as assessed by CT or MRI.
  2. Secondary Outcome Measures:

    1. Technical Success Rate: The percentage of procedures that achieve complete tumor ablation with a safety margin of at least 5 mm on the immediate post-procedure CT/MRI scan.
    2. Ablation Volume: The volume of the necrosis area created by the MWA procedure.
    3. Procedure Time: Time from the insertion to the removal of the MWA antenna.
    4. Safety: Incidence and severity of procedure-related complications, graded using the Clavien-Dindo classification system.
03

Conditions studied

  • Liver Malignant Tumors
04

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Class A or B
  • Patients with suspected hepatocellular carcinoma or residual/recurrent hepatocellular carcinoma of 4 cm or less on MDCT, CEUS, or MRI performed within the last 60 days or Patients with suspected liver cancer of 4 cm or less on MDCT, CEUS, or MRI performed within the last 60 days, for whom microwave thermal ablation is being considered

Exclusion criteria

Exclusion Criteria:

  • In cases where there are three or more malignant liver tumors
  • When the maximum size of the tumor exceeds 4 cm
  • Diffuse infiltrative type of cancer with unclear tumor boundaries
  • When the tumor is adhered to the central hepatic portal vein, hepatic vein, or bile duct by 5 mm or more
  • Severe liver failure ( Class C)
  • In cases of vascular invasion by malignant liver tumors
  • Severe coagulopathy ( count below 50,000/mm³ or prolonged by more than 50%)
  • In cases of multiple extrahepatic
  • Situations where it is highly unlikely to obtain appropriate data for research purposes
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    Experimental: Patients with Malignant Liver Tumors

    Following the existing procedure of our institute, we aim to treat the tumor by applying up to 150W of microwaves within the tumor using a StarWave microwave generator and a 13-gauge antenna under fusion ultrasound guidance. If necessary, the antenna is reinserted 1-2 times to create sufficient ablation lesions until an echogenic band of 5-10mm is formed around the tumor and its periphery, implementing overlapping microwave ablation (MWA). Afterward, the antenna is removed while applying microwave energy to prevent bleeding.

    Device: Starwave Microwave Ablation System · Procedure: Microwave Ablation · Device: Ultrasound-CT fusion guidance system · Drug: Local anesthesia and Conscious sedation

Interventions

  • DeviceStarwave Microwave Ablation System

    A microwave ablation system consisting of the Starwave™ microwave generator and a 13-gauge Starwave™ antenna. The generator has a maximum power output of 150W and is manufactured by STARmed Co., Ltd..

  • ProcedureMicrowave Ablation

    Under fusion ultrasound guidance, one or two 13-gauge antennas are used to apply up to 150W of microwave energy to the tumor. Overlapping ablation is performed as needed to create an echogenic safety margin of 5-10 mm around the tumor. To prevent bleeding, the antenna is removed while applying energy ("hot withdrawal").

  • DeviceUltrasound-CT fusion guidance system

    Fusion imaging of real-time ultrasound and pre-acquired CT/MRI will be used to guide the antenna placement and monitor the ablation process.

  • DrugLocal anesthesia and Conscious sedation

    Local anesthesia (e.g., 2% Lidocaine) and conscious sedation (e.g., Fentanyl and Midazolam) will be administered to the patient during the procedure

06

What researchers measure

Primary outcomes

  1. Technical success

    Technical success addresses whether the index tumor was treated according to a predefined protocol and entirely covered by the ablation zone.

    Time frame: Immediately after ablation

  2. Local tumor progression rate

    Local tumor progression, defined as the appearance of tumor foci at the margin of the ablation zone after the attainment of treatment success

    Time frame: 12 months after ablation

Secondary outcomes

  1. Complication after ablation

    Post ablation complications were defined as problems noted within 1 month after MWA as well as additional complications identified on follow-up imaging and judged to be likely caused by ablation.

    Time frame: Immediately, 1 month, 3 months, 6 months, 9 months, and 12 months after radiofrequency ablation

  2. Recurrence-free survival

    Recurrence-free survival was defined as the interval between ablation and the date of any type of recurrence or the last follow-up date if there was no recurrence.

    Time frame: 12 months after ablation

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Aug 2026, 28 months after the start.

Of 361 non-industry interventional studies with no phase under Carcinoma, Hepatocellular, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 28 months is below that.

Counting every sponsor, half of 385 studies reached it within 47 months; a quarter within 23 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2024
First posted
May 23, 2024
StartActual
Apr 30, 2024
Primary completionEst.
Aug 30, 2026
CompletionEst.
Aug 30, 2026
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06426992
Responsible party
Jeong Min Lee (Professor, Seoul National University Hospital) — Principal investigator
First posted
May 23, 2024
Start date
Apr 30, 2024
Primary completion
Aug 30, 2026 (estimated)
Completion
Aug 30, 2026 (estimated)
Last update
Apr 13, 2026

Study contacts

Hyun Hee Lee
Contact
redlion55@naver.com
82-2-2072-4177

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion